論文

査読有り 筆頭著者
2013年5月

Characteristics of Lung Cancers Harboring NRAS Mutations

CLINICAL CANCER RESEARCH
  • Kadoaki Ohashi
  • Lecia V. Sequist
  • Maria E. Arcila
  • Christine M. Lovly
  • Xi Chen
  • Charles M. Rudin
  • Teresa Moran
  • David Ross Camidge
  • Cindy L. Vnencak-Jones
  • Lynne Berry
  • Yumei Pan
  • Hidefumi Sasaki
  • Jeffrey A. Engelman
  • Edward B. Garon
  • Steven M. Dubinett
  • Wilbur A. Franklin
  • Gregory J. Riely
  • Martin L. Sos
  • Mark G. Kris
  • Dora Dias-Santagata
  • Marc Ladanyi
  • Paul A. Bunn
  • William Pao
  • 全て表示

19
9
開始ページ
2584
終了ページ
2591
記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.1158/1078-0432.CCR-12-3173
出版者・発行元
AMER ASSOC CANCER RESEARCH

Purpose: We sought to determine the frequency and clinical characteristics of patients with lung cancer harboring NRAS mutations. We used preclinical models to identify targeted therapies likely to be of benefit against NRAS-mutant lung cancer cells.
Experimental Design: We reviewed clinical data from patients whose lung cancers were identified at six institutions or reported in the Catalogue of Somatic Mutations in Cancer (COSMIC) to harbor NRAS mutations. Six NRAS-mutant cell lines were screened for sensitivity against inhibitors of multiple kinases (i.e., EGFR, ALK, MET, IGF-1R, BRAF, PI3K, and MEK).
Results: Among 4,562 patients with lung cancers tested, NRAS mutations were present in 30 (0.7%; 95% confidence interval, 0.45%-0.94%); 28 of these had no other driver mutations. 83% had adenocarcinoma histology with no significant differences in gender. While 95% of patients were former or current smokers, smoking-related G:C>T:A transversions were significantly less frequent in NRAS-mutated lung tumors than KRAS-mutant non-small cell lung cancer [NSCLC; NRAS: 13% (4/30), KRAS: 66% (1772/2733), P < 0.00000001]. Five of 6 NRAS-mutant cell lines were sensitive to the MEK inhibitors, selumetinib and trametinib, but not to other inhibitors tested.
Conclusion: NRAS mutations define a distinct subset of lung cancers (similar to 1%) with potential sensitivity to MEK inhibitors. Although NRAS mutations are more common in current/former smokers, the types of mutations are not those classically associated with smoking. Clin Cancer Res; 19(9); 2584-91. (C) 2013 AACR.

リンク情報
DOI
https://doi.org/10.1158/1078-0432.CCR-12-3173
Web of Science
https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=JSTA_CEL&SrcApp=J_Gate_JST&DestLinkType=FullRecord&KeyUT=WOS:000318361900031&DestApp=WOS_CPL
ID情報
  • DOI : 10.1158/1078-0432.CCR-12-3173
  • ISSN : 1078-0432
  • Web of Science ID : WOS:000318361900031

エクスポート
BibTeX RIS